DK2955195T3 - Antisemaphorin-3a-antistof og behandling af alzheimers sygdom og inflammatoriske immunsygdomme ved anvendelse af samme - Google Patents

Antisemaphorin-3a-antistof og behandling af alzheimers sygdom og inflammatoriske immunsygdomme ved anvendelse af samme Download PDF

Info

Publication number
DK2955195T3
DK2955195T3 DK14749177.3T DK14749177T DK2955195T3 DK 2955195 T3 DK2955195 T3 DK 2955195T3 DK 14749177 T DK14749177 T DK 14749177T DK 2955195 T3 DK2955195 T3 DK 2955195T3
Authority
DK
Denmark
Prior art keywords
antisemaphorin
alzheimer
antibody
disease
treatment
Prior art date
Application number
DK14749177.3T
Other languages
English (en)
Inventor
Yoshio Goshima
Fumio Nakamura
Naoya Yamashita
Hidetaka Seo
Shuichi Hashimoto
Koji Murakami
Naoki Takahashi
Yukie Sasakura
Original Assignee
Univ Yokohama City
Chiome Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yokohama City, Chiome Bioscience Inc filed Critical Univ Yokohama City
Application granted granted Critical
Publication of DK2955195T3 publication Critical patent/DK2955195T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
DK14749177.3T 2013-02-06 2014-02-06 Antisemaphorin-3a-antistof og behandling af alzheimers sygdom og inflammatoriske immunsygdomme ved anvendelse af samme DK2955195T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013021309 2013-02-06
PCT/JP2014/052758 WO2014123186A1 (ja) 2013-02-06 2014-02-06 抗セマフォリン3a抗体、並びにこれを用いたアルツハイマー病及び免疫・炎症性疾患の治療

Publications (1)

Publication Number Publication Date
DK2955195T3 true DK2955195T3 (da) 2019-05-06

Family

ID=51299777

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14749177.3T DK2955195T3 (da) 2013-02-06 2014-02-06 Antisemaphorin-3a-antistof og behandling af alzheimers sygdom og inflammatoriske immunsygdomme ved anvendelse af samme

Country Status (6)

Country Link
US (3) US9879075B2 (da)
EP (1) EP2955195B1 (da)
JP (1) JP6372040B2 (da)
DK (1) DK2955195T3 (da)
ES (1) ES2728854T3 (da)
WO (1) WO2014123186A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2497498A4 (en) * 2009-11-05 2013-04-17 Univ Osaka THERAPEUTIC ACTIVE FOR AUTOIMMUNE DISEASES OR ALLERGIES AND METHOD FOR SCREENING AFTER THE THERAPEUTIC ACTIVE SUBSTANCE
US9822367B2 (en) 2013-02-21 2017-11-21 Rsem, Limited Partnership Inhibition of SEMA3A in the prevention and treatment of ocular hyperpermeability
US10105413B2 (en) * 2013-06-13 2018-10-23 Medical Research & Development Fund for Health Services Bnai Zion Medical Center Semaphorin 3A for treatment of systemic lupus erythematosus
JP6692816B2 (ja) 2014-09-05 2020-05-13 アールエスイーエム,リミティド パートナーシップ 炎症を処置および予防するための組成物および方法
AU2016270373A1 (en) 2015-06-05 2018-01-04 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
US10688178B2 (en) 2015-06-30 2020-06-23 Osaka University AntiPlexin A1 agonist antibody
US10604572B2 (en) 2015-10-27 2020-03-31 Samsung Life Public Welfare Foundation Antibody to human and mouse Sema3A and use thereof
KR101854529B1 (ko) * 2015-10-27 2018-05-04 (주) 팬젠 인간 및 마우스 Sema3A에 교차결합하는 항체 및 그의 용도
WO2017074013A1 (ko) * 2015-10-27 2017-05-04 사회복지법인 삼성생명공익재단 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도
US10640777B2 (en) 2015-10-27 2020-05-05 Samsung Life Public Welfare Foundation Antibody to human and mouse SEMA3A and use thereof
US10604571B2 (en) 2015-10-27 2020-03-31 Samsung Life Public Welfare Foundation Antibody to human and mouse SEMA3A and use thereof
KR20190114963A (ko) * 2016-12-02 2019-10-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 에볼라 바이러스에 대한 사용을 위한 dna 항체 작제물
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
EP3581645B1 (en) 2017-02-10 2021-09-01 Chiome Bioscience Inc. Method for promoting diversification of antibody variable region
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
MX2021013671A (es) 2019-05-09 2021-12-10 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares.
WO2020261281A1 (en) * 2019-06-27 2020-12-30 Ramot At Tel-Aviv University Ltd. Semaphorin 3a antibodies and uses thereof
US12560598B2 (en) 2020-03-11 2026-02-24 Genesis Intelligence, Llc Cartridge-based automated rapid test analyzer
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
CN116490208A (zh) * 2020-08-06 2023-07-25 史坦利科西斯治疗有限责任公司 Il-8抗体及其使用方法
US20220127344A1 (en) 2020-10-23 2022-04-28 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
WO2022185742A1 (ja) * 2021-03-01 2022-09-09 学校法人埼玉医科大学 播種性血管内凝固症候群の予防又は治療用組成物
WO2022207554A1 (en) * 2021-03-30 2022-10-06 Bayer Aktiengesellschaft Anti-sema3a antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1418834A4 (en) 2001-07-20 2007-04-04 Sinai School Medicine METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE AND PARKINSON DISEASE
AU2005214382B2 (en) 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
EP2497498A4 (en) * 2009-11-05 2013-04-17 Univ Osaka THERAPEUTIC ACTIVE FOR AUTOIMMUNE DISEASES OR ALLERGIES AND METHOD FOR SCREENING AFTER THE THERAPEUTIC ACTIVE SUBSTANCE
US8871205B2 (en) * 2009-11-25 2014-10-28 The University Of North Carolina At Chapel Hill Methods and compositions for the treatment of immune disorders

Also Published As

Publication number Publication date
ES2728854T3 (es) 2019-10-29
JP6372040B2 (ja) 2018-08-15
US20210095012A1 (en) 2021-04-01
WO2014123186A1 (ja) 2014-08-14
US20150368327A1 (en) 2015-12-24
US10836814B2 (en) 2020-11-17
JPWO2014123186A1 (ja) 2017-02-02
EP2955195A4 (en) 2016-11-02
EP2955195A1 (en) 2015-12-16
US20180208644A1 (en) 2018-07-26
EP2955195B1 (en) 2019-03-27
US9879075B2 (en) 2018-01-30

Similar Documents

Publication Publication Date Title
DK2955195T3 (da) Antisemaphorin-3a-antistof og behandling af alzheimers sygdom og inflammatoriske immunsygdomme ved anvendelse af samme
DK2994160T3 (da) Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g
DK3221349T3 (da) Humaniserede tau-antistoffer i Alzheimers sygdom
EP3556773A4 (en) HUMAN ANTI-CD73 ANTIBODY
DK3024497T3 (da) Fremgangsmåder og præparater til behandling af hjernesygdomme
IL257065A (en) Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders
IL256079A (en) Humanized and affinity matured antibodies to fcrh5 and methods of use
EP2965277A4 (en) PREDICTION OF APPROVAL OF TRANSACTIONS
IL249195A0 (en) Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
IL240509B (en) Fluorescence imaging of inflammatory diseases
HUE049569T2 (hu) Immunrendszerrel kapcsolatos és gyulladásos megbetegedések kezelése
EP2954065A4 (en) PARTITIONING AND PROCESSING OF ANALYTES AND OTHER SPECIES
DK2903967T6 (da) Acylaminopyrimidinderivater til behandling af virusinfektioner og andre sygdomme
EP2948149A4 (en) BY TOXIC ALDEHYDIC DISEASES AND TREATMENT
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
HRP20182069T1 (hr) Farmaceutski pripravci za liječenje alzheimerove bolesti
HUE054783T2 (hu) Pridopidin Huntington-kór kezelésében
EP3011515A4 (en) LANGUAGE TRANSACTION PROCESSING
CL2016001519A1 (es) Anticuerpos anti-tau(ps422) humanizados y métodos de utilización
DK3081568T3 (da) Sammensætninger og fremgangsmåder til behandling af alzheimers sygdom
HUE051632T2 (hu) Betegségek kezelésére szolgáló készítmények és eljárások
DK2968470T3 (da) Modificeret müllersk inhiberende substans (mis)-proteiner og anvendelser deraf til behandlingen af sygdomme
IL269158A (en) Compositions and methods for treating inflammatory diseases
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
DK3347002T3 (da) Behandling af alzheimers sygdom i en bestemt patientpopulation